MSLN and neoplasm: The local inhibitory checkpoint monoclonal antibody (LicMAb) binds mesothelin (MSLN) with high affinity and simultaneously blocks CD47 on MSLN-expressing tumor cells to inhibit the “don’t eat me” signal.